Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Ontology highlight
ABSTRACT: The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment of patients with RAS wild type metastatic CRC.
DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Valproic Acid
PROVIDER: 5791 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA